Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23537595 | 0.85 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL9802809 | 0.83 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL23537555 | 0.70 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PIM1PIM3 | |
| SCHEMBL9803021 | 0.70 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL17895743 | 0.70 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL9803330 | 0.70 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL19002374 | 0.70 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PIM1PIM3HPGD | |
| SCHEMBL29078346 | 0.68 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDMAPTMAOA | |
| SCHEMBL21096156 | 0.68 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDMAPTMAOA | |
| SCHEMBL21087040 | 0.68 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693484-B | Simple synthesis method of 1-bromodibenzofuran | 武汉理工大学 | 2024-11-12 | — | — | CN | claimed |
| CN-116693484-A | Simple synthesis method of 1-bromodibenzofuran | 武汉理工大学 | 2023-09-05 | — | — | CN | claimed |
| EP-1632485-A1 | Method of producing 3,4,5,7,8,9-hexahydro-2h-dibenzofuran-1-one | SK Corporation (KR) | 2006-03-08 | — | — | EP | claimed |
| CN-116693484-B | Simple synthesis method of 1-bromodibenzofuran | 武汉理工大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-116693484-A | Simple synthesis method of 1-bromodibenzofuran | 武汉理工大学 | 2023-09-05 | — | — | CN | disclosed |
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| WO-2017109724-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017109724-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| EP-1632485-A1 | Method of producing 3,4,5,7,8,9-hexahydro-2h-dibenzofuran-1-one | SK Corporation (KR) | 2006-03-08 | — | — | EP | disclosed |
| EP-1632485-A1 | Method of producing 3,4,5,7,8,9-hexahydro-2h-dibenzofuran-1-one | SK Corporation (KR) | 2006-03-08 | — | — | EP | disclosed |
| EP-1632485-A1 | Method of producing 3,4,5,7,8,9-hexahydro-2h-dibenzofuran-1-one | SK Corporation (KR) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961258-B2 | Heterocyclic amides as kinase inhibitors | CNKSR1, ARAF, BRAF | ALDH1A1 2165/4885SMN1; SMN2 4671/4885PIM1 802/4885 |
| US-20200270273-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, BRAF | ALDH1A1 2165/4885SMN1; SMN2 4671/4885PIM1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.